Advancing Accessible Solutions for Brain Health
Cognition Therapeutics (cogrx.com) scores 73 out of 100 on Brand Analyzer, placing it in the Brand-Ready tier among Healthcare brands, in the 34th percentile of 8299 Healthcare brands.
Cognition Therapeutics is a biopharmaceutical company headquartered in Pittsburgh, United States, founded in 2007. It develops accessible therapies aimed at protecting brain synapses to combat complex neurodegenerative diseases. Its lead candidate, zervimesine (CT1812), is a first-in-class, once-daily oral small-molecule therapy designed to preserve synaptic integrity before irreversible neuronal decline, targeting conditions such as Alzheimer's disease and dementia with Lewy bodies.
| Brand Name | Cognition Therapeutics |
|---|---|
| Domain | cogrx.com |
| Industry | Healthcare |
| Founded | 2007 |
| Headquarters | Pittsburgh |
| Main Competitors | Biogen (78/100), Eisai (80/100), Eli Lilly (78/100), Roche/Genentech (84/100), Cassava Sciences (52/100), Alector (79/100), Denali Therapeutics (77/100), AC Immune, Anavex Life Sciences (81/100), vTv Therapeutics |
Moz Domain Authority 40/100 vs category average 40 / leader 95 - a strong backlink profile, so AI systems frequently encounter mentions of the brand.
Ranked #2,296,412 on the Tranco list of most-visited sites - modest traffic makes the brand easy for AI models to overlook.
No Wikipedia presence was found - a major gap, since Wikipedia is among the most heavily weighted sources in AI training data.
The homepage meta description reads "To develop accessible therapies that protect brain synapses and combat complex neurodegenerative diseases." (No meta description) - this is the summary AI engines are most likely to quote.
Structured data on the homepage: Microdata (Schema.org), canonical. Adding Organization and FAQ schema would further help AI crawlers parse the brand's identity.
AI-crawler access: robots.txt present, no AI bot restrictions - robots.txt controls whether engines like GPTBot and ClaudeBot can read the site at all.
Detected tech stack: Cloudflare, WordPress, Ghost.
Social footprint: verified profiles on X (Twitter), LinkedIn, Facebook, Instagram; no detected presence on YouTube, GitHub - consistent profiles reinforce the brand's identity across the web.
0 Reddit mentions - community discussion signals real-world reputation to AI models.
Live results from asking a general-purpose AI assistant about the brand, checked September 2026.
When asked "What is Cognition Therapeutics?", Claude could identify the brand as of September 2026. Cognition Therapeutics is a clinical-stage biopharmaceutical company focused on developing therapies for neurodegenerative diseases, particularly Alzheimer's disease. Their lead candidate, CT1812 (zervimesine), works by targeting sigma-2 receptors to displace toxic amyloid-beta o Best known for developing CT1812 (zervimesine), a sigma-2 receptor modulator being tested for Alzheimer's disease and dementia with Lewy bodies.
When asked "Best brands similar to Cognition Therapeutics?", Claude would recommend Cognition Therapeutics as of September 2026. I'd mention it in the context of Alzheimer's drug development pipelines alongside other clinical-stage biotechs working on amyloid-targeting or neuroprotective therapies.
Common questions people ask in Google, ChatGPT, Claude, Gemini, Perplexity, and other AI search engines.
Cognition Therapeutics's main competitors in Healthcare: Biogen (78/100), Eisai (80/100), Eli Lilly (78/100), Roche/Genentech (84/100), Cassava Sciences (52/100).
Sources: Brand Analyzer scan
Cognition Therapeutics has limited AI-search visibility, scoring 32/100 on Brand Analyzer's AI visibility composite (visibility 21, trust 30, recommendation 53). This estimates how likely AI engines like ChatGPT, Claude, Gemini and Perplexity are to know, trust, and recommend the brand.
Sources: Cognition Therapeutics official site
Cognition Therapeutics was founded in 2007. Cognition Therapeutics operates in the Healthcare category. It is analyzed by Brand Analyzer across seven brand dimensions and AI-search visibility.
Sources: Wikidata
Cognition Therapeutics is headquartered in Pittsburgh. Cognition Therapeutics operates in the Healthcare category.
Sources: Wikidata
Cognition Therapeutics' primary offering is zervimesine (CT1812), a first-in-class, once-daily oral small-molecule therapy designed to protect synaptic integrity before irreversible neuronal decline occurs. It is being developed as a treatment approach for neurodegenerative diseases including Alzheimer's disease and dementia with Lewy bodies.
Sources: Cognition Therapeutics official site
Cognition Therapeutics scores 53/100 on Brand Analyzer's AI recommendation signal, indicating it is reasonably likely to be surfaced when AI assistants like ChatGPT suggest Healthcare options. Recommendation depends on crawlability, structured data, and category authority.
Sources: Cognition Therapeutics official site
Cognition Therapeutics is a biopharmaceutical company based in Pittsburgh, United States, founded in 2007. It focuses on developing disease-modifying treatments for complex neurodegenerative diseases by protecting brain synapses from damage.
Sources: Cognition Therapeutics official site
Cognition Therapeutics develops therapies intended to protect synaptic integrity in the brain, aiming to prevent irreversible neuronal decline associated with neurodegenerative diseases. Its work centers on zervimesine (CT1812), a first-in-class, once-daily oral small-molecule compound being studied for conditions such as Alzheimer's disease and dementia with Lewy bodies.
Sources: Cognition Therapeutics official site
Cognition Therapeutics can improve AI discoverability by strengthening structured data (Organization and FAQ schema), maintaining an accurate Wikipedia/Wikidata entity, earning authoritative citations, and keeping content crawlable for AI bots. Brand Analyzer measures these as visibility, trust, and recommendation signals.
Sources: Cognition Therapeutics official site
Cognition Therapeutics is known for developing zervimesine (CT1812), described as a first-in-class, once-daily oral small-molecule therapy designed to protect synaptic integrity in patients with neurodegenerative diseases like Alzheimer's disease and dementia with Lewy bodies.
Sources: Cognition Therapeutics official site
The intended users of Cognition Therapeutics' work include patients with neurodegenerative diseases such as Alzheimer's disease and dementia with Lewy bodies, along with their caregivers, healthcare providers, and the broader medical and investment communities who follow or support the company's drug development efforts.
Sources: Cognition Therapeutics official site
Cognition Therapeutics scores 32/100 for AI visibility - how well ChatGPT, Claude, Perplexity and Google AI Overviews can discover, identify and cite the brand.
Cognition Therapeutics has a weak AI-visibility profile at 32/100 - a proxy for how readily ChatGPT, Perplexity and Google's AI Overviews can recognise and cite it. Its strongest area is recommendation likelihood (53/100) and its weakest is visibility (21/100). It benefits from a Wikidata knowledge-graph entry, a global traffic rank of #2,296,412 (Tranco) and a Moz Domain Authority of 40/100. The main gaps holding it back: no clear Wikipedia entity to anchor it in LLM training data, thin schema.org structured data and no llms.txt to steer AI to its best pages. In a live check, Claude could already identify Cognition Therapeutics from memory (September 2026) - a sign these signals are paying off.
The score combines seven dimensions - name quality, digital presence, visual identity, messaging clarity, trust foundation, AI discoverability, and brand authority - into a single objective benchmark.
Ranked closest to Cognition Therapeutics: Codex Health (73/100), Central Maine Healthcare (73/100), ConnectABILITY (73/100), Copley Scientific (73/100).
A step up - brands to learn from: Zurich Insurance Group (81/100), ZOLL Data Systems (81/100).
Category leader: Booksy (96/100).
Brand Analyzer is built by DataEase AI. Track your brand in ChatGPT, Gemini and Perplexity.